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ChemotaxisInﬂammation occurs as a result of exposure of tissues and organs to harmful stimuli such asmicrobial pathogens,
irritants, or toxic cellular components. The primary physical manifestations of inﬂammation are redness, swell-
ing, heat, pain, and loss of function to the affected area. These processes involve the major cells of the immune
system, including monocytes, macrophages, neutrophils, basophils, dendritic cells, mast cells, T-cells, and B-
cells. However, examination of a range of inﬂammatory lesions demonstrates the presence of speciﬁc leukocytes
in any given lesion. That is, the inﬂammatory process is regulated in such a way as to ensure that the appropriate
leukocytes are recruited. These events are in turn controlled by a host of extracellular molecular regulators, in-
cluding members of the cytokine and chemokine families that mediate both immune cell recruitment and com-
plex intracellular signalling control mechanisms that characterise inﬂammation. This review will focus on the
role of the main cytokines, chemokines, and their receptors in the pathophysiology of auto-inﬂammatory disor-
ders, pro-inﬂammatory disorders, and neurological disorders involving inﬂammation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The last 50 years has witnessed a rapid growth in research into in-
ﬂammatory diseases. This advance of information has led researchers
and physicians to begin to redeﬁne many diseases including heart dis-
ease, Alzheimer's disease, type 1 diabetes, type 2 diabetes and obesity
as inﬂammatory disorders. Much of this new view has come from re-
search showing that people with chronic inﬂammatory diseases have
elevated blood levels of C-reactive protein and other markers of inﬂam-
mation [1,2]. Relatively minor inﬂammatory disorders, such as injuries
or allergies, can also set the stage formore serious chronic inﬂammatory
diseases, andmany inﬂammatory disorders actually develop as clusters.
Inﬂammation is controlled by a host of extracellular mediators and
regulators, including cytokines, growth factors, eicosanoids (prosta-
glandins, etc), complement and peptides. In fact, it is the discovery of
many of these mediators over the past 20 years that has increased our
understanding of the regulation of the inﬂammatory process whilst, at
the same time, revealing its complexity. These extracellular events are
matched by equally complex intracellular signalling control mecha-
nisms, governed by the ability of cells to assemble and disassemble a
complex array of signalling pathways as they move from inactive to
dedicated roles within the inﬂammatory response site. This reviewechnology, Nottingham Trent
gdom. Tel.:+44 115 848 3113.will focus on the role of themain cytokine and chemokine cell signalling
molecules, andhowdisruption of these pathways triggers inﬂammatory
disorders.
2. Cytokine signalling
Cytokines are keymodulators of inﬂammation, participating in acute
and chronic inﬂammation via a complex and sometimes seemingly con-
tradictory network of interactions. Better understanding of how these
pathways are regulated helps facilitate more accurate identiﬁcation of
agents mediating inﬂammation and the treatment of inﬂammatory dis-
eases. It is possible to classify cytokines based on the nature of the im-
mune response (Table 1), with individual cytokines also performing
speciﬁc roles dependent upon cell type and location (Table 2). Key
pro-inﬂammatory cytokines include interleukin-1 (IL-1), IL-6 and tu-
mour necrosis factor (TNFα), all of which signal via the type I cytokine
receptors that are structurally divergent from other cytokine receptor
types. By contrast, the critical pro-inﬂammatory chemokine, IL-8, sig-
nals via G protein-coupled receptors (GPCRs) (Fig. 1). The major pro-
inﬂammatory cytokines, their receptor-mediated signalling pathways,
and their contribution to human disease are discussed below.
2.1. Interleukin-1 (IL-1)
The IL-1 family now includes 11 members: IL-1α, IL-1β, the IL-1 re-
ceptor antagonist [IL-1Ra], IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra,
Table 1
Classiﬁcation of cytokines by immune response. Cytokines can be broadly grouped based on whether they act on cells of the adaptive immune response, or promote or inhibit
inﬂammation. Further, they can be classiﬁed based on the receptors used for signalling.
Family Members
Adaptive immunity Common γ chain receptor ligands IL-2, IL-4, IL-7, IL-9, IL-15, IL-21
Common β chain (CD131) receptor ligands IL-3, IL-5, GM-CSF
Shared IL-2β chain (CD122) IL-2, IL-15
Shared receptors IL-13 (IL-13R–IL-4R complex)
TSLP (TSLPR–IL-7R complex)
Pro-inﬂammatory signalling IL-1 IL-1α, IL-1β, IL-1ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37 and IL-1Hy2
IL-6 IL-6, IL-11, IL-31, CNTF, CT-1, LIF, OPN, OSM
TNFα TNFα, TNFβ, BAFF, APRIL
IL-17 IL-17A-F, IL-25 (IL-17E)
Type I IFN IFNα, IFNβ, IFNω, IFNκ, Limitin
Type II IFN IFNγ
Type III IFN IFNλ1 (IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B)
Anti-inﬂammatory signalling IL-12 IL-12, IL-23, IL-27, IL-35
IL-10 IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29
Abbreviations: CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; GM-CSF, granulocytemacrophage-colony stimulating factor; IFN, interferon; LIF, leukaemia inhibitory factor; OPN,
osteopontin; OSM, oncostatin M; TNFα, tumour necrosis factor α; TSLP, thymic stromal lymphopoietin.
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types, including macrophages and monocytes, and comprise both pro-
and anti-inﬂammatory members [3]. Of these, IL-1β is a potent pro-
inﬂammatory cytokine that was originally identiﬁed as an endogenous
pyrogen. Further, IL-1β and has been found to have a stimulatory effect
on CD4+T cells and to promote differentiation into the T helper cell lin-
eages, particularly T helper (Th17) cells and a non-classically derived
Th1 cell lineage [4]. Given its central role in mediating a wide array of
inﬂammatory signalling responses, we will mainly discuss the actions
of the pro-inﬂammatory cytokine, IL-1β, in this section.
IL-1α and IL-1β are synthesised by multiple cell types including
monocytes, macrophages, neutrophils, hepatocytes, and tissueTable 2
Functions of cytokines. Cytokine action, deﬁned by target cell and primary function.
Cytokine Main sources Target cell
Interleukins IL-1 Macrophages, B cells, DCs B cells, NK cells, T-cells
IL-2 T cells Activated T and B cells,
NK cells
IL-3 T cells, NK cells Stem cells
IL-4 Th cells B cells, T cells,
macrophages
IL-5 Th cells Eosinophils, B-cells
IL-6 Th cells, macrophages,
ﬁbroblasts
Activated B-cells,
plasma cells
IL-7 BM stromal cells,
epithelial cells
Stem cells
IL-8 Macrophages Neutrophils
IL-9 T cell T cell
IL-10 T cell B cells, macrophages
IL-11 BM stromal cells B cells
IL-12 T cells NK cells
Tumour necrosis
factors
TNF-α Macrophages Macrophages
Monocytes Tumour cells
TNF-β T-cells Phagocytes, tumour
cells
Interferons IFN-α Leukocytes Various
IFN-β Fibroblasts Various
IFN-γ T-cells Various
Colony stimulating
factors
G-CSF Fibroblasts, endothelium Stem cells in BM
GM-CSF T cells, macrophages,
ﬁbroblasts
Stem cells
M-CSF Fibroblast, endothelium Stem cells
Erythropoietin Endothelium Stem cells
Others TGF-β T cells and B cells Activated T and B cells
Abbreviations: BM, bone marrow; DCs, dendritic cells; G-CSF, granulocyte-colony stimulatingmacrophages throughout the body [5]. Whereas the expression of IL-
1α is constitutive in many cell types, by contrast IL-1β expression is
induced mainly in response to microbial molecules, although it can
also stimulate its own expression [6]. Stimulation of pattern recognition
receptors (PRRs) including Toll-like receptors (TLRs) and NOD-like
receptors (NLLs) can be induced both by viral and microbial molecules.
This can then lead to the induction of IL-1β expression [7,8]. Members
of the IL-1 family, including IL-1β, are typically synthesised as precur-
sors without a secretory sequence. IL-1βmust therefore be cleaved in
order to generate active cytokine [9] and this is performed by the IL-
1-converting enzyme (ICE), or caspase-1, which is contained within a
specialised intracellular complex termed the inﬂammasome [6]. InMajor function
Pyrogenic, pro-inﬂammatory, proliferation and differentiation, BM cell proliferation
Proliferation and activation
Hematopoietic precursor proliferation and differentiation
Proliferation of B and cytotoxic T cells, enhances MHC class II expression, stimulates
IgG and IgE production
Proliferation and maturation, stimulates IgA and IgM production
Differentiation into plasma cells, IgG production
B and T cell growth factor
Chemotaxis, pro-inﬂammatory
Growth and proliferation
Inhibits cytokine production and mononuclear cell function, anti-inﬂammatory
Differentiation, induces acute phase proteins
Activates NK cells
Phagocyte cell activation, endotoxic shock
Tumour cytotoxicity, cachexia
Chemotactic, phagocytosis, oncostatic, induces other cytokines
Anti-viral
Anti-viral, anti-proliferative
Anti-viral, macrophage activation, increases neutrophil andmonocyte function,MHC-I
and -II expression on cells
Granulocyte production
Granulocyte, monocyte, eosinophil production
Monocyte production and activation
Red blood cell production
Inhibit T and B cell proliferation, inhibit haematopoiesis, promote wound healing
factors; M-CSF, macrophage colony stimulating factor; Th, T helper cells.
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Fig. 1. Cytokines, chemokines and their receptors. Cytokines signal via oligomers of single-pass, type I transmembrane receptors, with distinct extracellular domains for ligand binding and
intracellular domains that allow signal transduction. The receptor for IL-1 is a complex of IL-1R1 and the IL-1RAcP formed following ligand binding to the extracellular immunoglobulin
domains (IGDs); intracellular signalling is mediated via the Toll/IL-1R (TIR) domain. Trimeric TNFα binds to the cysteine-rich domains (CRDs) of the pre-assembled trimmers of the TNF
receptor (TNFR) and signalling is mediated via the receptor's death domain (DD). Finally, the IL-6R is a multimeric structure with IL-6R chains complexedwith gp130. The ligand-binding
region is within the ﬁbronectin III (FIII) modules of the IL-6R chains but signal transduction is via the associated gp130 molecules. Chemokine signalling occurs via activation of the seven
transmembrane G protein-coupled receptors (GPCRs). IL-8 binds to the extracellular face of either CXCR1 or CXCR2, triggering a conformational change that results in the activation of the
G-proteins. Abbreviations: FIII module, ﬁbronectin III module; GAGs, glycosaminoglyans.
2565M.D. Turner et al. / Biochimica et Biophysica Acta 1843 (2014) 2563–2582contrast, IL-1α is active in both its precursor and mature forms but
typically remains in the nucleus, the cytoplasm, or on the cell mem-
brane [9]. Despite these differences, IL-1α and IL-1β have similar afﬁn-
ities for the two IL-1 receptors, IL-1R1 and IL-1R2. The heterodimeric
complex of IL-1R1 and the IL-1R accessory protein (IL-1RAcP) consti-
tutes the functional receptor for IL-1 [10]. Normally, IL-1β binds ﬁrst
to IL-1R1 on the surface of target cells and then the IL-1RAcP is recruit-
ed, thus forming a trimolecular signalling complex (Fig. 2). IL-1R
belongs to the IL-1R/TLR superfamily due to the presence a conserved
cytoplasmic Toll/IL-1R (TIR) domain [10]. Following ligand binding
the adaptor molecule, MyD88, interacts with IL-1R1 via its TIR domain
[10]. Signal transduction leads to activation of both mitogen-activated
protein kinases (MAPKs) and the transcription factor NF-κB, thereby
resulting in pro-inﬂammatory cytokine expression. In addition to
this classical signalling pathway, there is also evidence that regulat-
ed intramembrane proteolysis of IL-1R1 generates both a soluble
ectodomain and an intracellular domain, with the latter directly modu-
latingMAPK activation [11]. Thus, proteolytic processing of cytosolic re-
ceptors could contribute to signalling by a non-canonical mechanism.
The IL-1 family also includes members that have an inhibitory role,
enabling them to suppress signalling and thereby limit inﬂammatory
response. Firstly, IL-1R2has aminimal intracellular domain that renders
it inactive, and thus signalling is not induced following ligand binding.
IL-1R2 is therefore thought to act as a decoy receptor, sequestering IL-
1 in an anti-inﬂammatory mechanism [6]. Secondly, The IL-1R antago-
nist (IL-1Ra) is able to bind to the IL-1R1 and, in doing so, prevents
the recruitment of IL-1RAcP [3], thereby inhibiting signal transduction.
IL-1Ra is expressed as one of four different isoforms, generated by alter-
native splicing, including one secreted form (sIL-1Ra) and three cytosol-
ic forms [12]. It is secreted by a number of cell types, including
neutrophils, macrophages, monocytes and hepatocytes [12]. The sIL-
1Ra is one of the acute phase proteins secreted by the liver in response
to inﬂammatory stimuli [12]. Its absence is deleterious, with IL-1Ra-
deﬁcientmice being prone to the development of various inﬂammatory
disorders and more susceptible to the effects of experimental immune
challenges [13,14]. Despite this ﬁnding, the efﬁcacy of IL-1Ra is thought
to be much lower relative to that of agonist, resulting in the need for a
up to 1000-fold excess IL-1RA in order to inhibit IL-1 signalling [15].
This is potentially due to the high level of IL-1R1 expression on most
cells to which IL-1Ramay bind, while Il-1 itself need only bind a few re-
ceptors to trigger signal transduction [15]. Given that three of theisoforms of IL-1Ra are intracellular, it has been hypothesised that the
critical site of IL-1Ra could be a cytosolic location where it could block
IL-1 expression or signalling by altering mRNA stability [12]. Thus,
while IL-1Ra acts as a natural suppressor of inﬂammation, on its own
it might be insufﬁcient to quell IL-1 signalling and its function could
be more complex, involving intracellular modulation of IL-1.
2.2. Tumour necrosis factor (TNFα)
The term tumour necrosis factor was initially conferred to two mol-
ecules, TNFα a monocyte-derived tumour necrosis factor, and TNFβ a
lymphocyte-derived tumour necrosis factor, Tumour necrosis factor
(TNFα) was initially identiﬁed in the 1970s as an endotoxin-induced
serum factor responsible for the necrosis of certain tumours in vivo
and in vitro [16]. Subsequently TNFα was isolated [17] and its gene
cloned [18]. It is a potent inﬂammatory mediator that is central to the
inﬂammatory action of the innate immune system, including induction
of cytokine production, activation or expression of adhesion molecules,
and growth stimulation [19–22]. It stimulates the proliferation of nor-
mal cells, exerts cytolytic or cytostatic activity against tumour cells,
and causes inﬂammatory, antiviral, and immunoregulatory effects
[23]. TNFα has also been shown to perform a number of additional func-
tions linked with lipid metabolism, coagulation, insulin resistance, and
endothelial function. Indeed, it has been shown to be one of the most
important and pleiotropic cytokines mediating inﬂammatory and im-
mune responses.
TNFα is the prototypic member of the TNF superfamily of type II
transmembrance proteins that includes 30 receptors and 19 associated
ligands with diverse functions in cell differentiation, inﬂammation,
immunity and apoptosis [24]. It is primarily secreted from activated
macrophages, although it may also be secreted by other cell types in-
cludingmonocytes, T cells,mast cells, NK cells, keratinocytes,ﬁbroblasts
and neurons [25]. TNFα is synthesised as a transmembrane precursor
protein (mTNFα) with a molecular mass of 26 kDa [25], after which it
is transported via the rough endoplasmic reticulum (RER), Golgi com-
plex and the recycling endosome to the cell surface [26]. Themonomers
of TNFα associate at the plasmamembrane as non-covalent trimers [27,
28] prior to being cleaved by the metalloprotease, TNFα converting en-
zyme (TACE or ADAM17) [29]. Cleavage by TACE results in the produc-
tion of 17 kDa soluble TNFα (sTNFα) ectodomain and it is trimers of
sTNFα that constitute the potent ligand that activates TNF receptors
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Fig. 2. IL-1 signal transduction toNF-κB activation. IL-1 binds to the IL-1R, which associateswith the IL-1RAcP at the cell surface, and signals via the TIR adaptor,MyD88, through homotypic
TIR-TIR interactions. Subsequently, IL-1R associated kinases (IRAKs) are recruited to the receptor/MyD88 complex. Activated IRAKs promote TNFR-associated factor 6 (TRAF6)
polyubiquitination via lysine 63 linkages. The polyubiquitinated TRAF6 interacts with TAK1 in complex with TAB1 and TAB2, ultimately leading to the phosphorylation of IκBα and its
dissociation from NF-κB subunits. The phosphorylated IκBα is subsequently ubiquitinated for degradation by the proteasome. The phosphorylated p65/p50 heterodimer translocates
to the nucleus, where it binds to response elements in NF-kB-dependent genes and leads to the induction of pro-inﬂammatory gene expression. In addition, the activation of TAK1/
TAB1/TAB2 leads to the phosphorylation and activation of the mitogen-activated protein kinases (MAPKs), JNK and p38. These kinases then phosphorylate and activate transcription
factors, thereby inducing the expression of pro-inﬂammatory genes. Abbreviations: IKK, IκB kinase; IκBα, inhibitor of κB; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor
κB; TAB1, TAK1 binding protein 1; TAB2, TAK1 binding protein 2; TAK1, transforming growth factorβ-activated kinase 1.
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processed by the signal peptide peptidases (SPPLs) SPPL2a and SPPL2b
[30]. This cleavage produces an intracellular domain (ICD) that translo-
cates to the nucleus and induces pro-inﬂammatory cytokine signalling,
particularly the expression of IL-12 [30]. Thus, the precursor TNFαmol-
ecule is subjected tomultiple cleavage events to release potentmodula-
tors of inﬂammation.
The molecular actions of extracellular sTNFα and mTNFα typically
occur through binding to one of two receptors: TNFR1 (TNFRSF1A,
p55TNFR1, p60, CD120a) and TNFR2 (TNFRSF1B, p75TNFR, p80 or
CD120b) [25]. The receptors are expressed on different cell types, with
TNFR1 beingwidely expressed, while TNFR2 is expressed predominant-
ly on leukocytes and endothelial cells [31]. The two TNFRs have been
reported to mediate distinct biological effects. Knockout mice for
TNFRSF1A (TNFR1) are resistant to endotoxic shock, but they are much
more susceptible than either TNFRSF1B (TNFR2) knockouts or wild
type controls to challenge with Listeria monocytogenes [32]. Thus, pro-
inﬂammatory effects of TNFα appear to be mediated predominantly
through TNFR1.
Both TNFR1 and TNFR2 are single transmembrane glycoproteins
with 28% homology in their extracellular domains [27]. Common fea-
tures in this region include four cysteine-rich domains (CRDs), each of
which comprises three cysteine-cysteine disulphide bonds, and a pre-
ligand binding assembly domain (PLAD) involved in trimerisation of
the receptor [33]. Importantly, the receptors differ by the presence of
an intracellular death domain (DD) at the carboxyl-end of TNFR1 [27]
that is able to drive either apoptosis or inﬂammation throughinteraction with associated adaptor molecules (Fig. 3). Recruitment of
TRADD to TNFR1 is required for both signalling pathways [34]. Subse-
quently, one of two complexes is formed, either at the cell surface (com-
plex I) or following internalisation (complex II) [35]. The formation of
complex I requires TNFR-associated factor 2 (TRAF2) and receptor-
interacting protein (RIP), leading to kinase cascades that trigger pro-
inﬂammatory gene expression. Alternatively, should the ﬁrst complex
fail to signal, Complex II is formed to induce apoptosis [35]. In Complex
II, proteolysis and internalisation of the receptor results in the recruit-
ment of FADD and pro-caspase-8 to form the death-inducing signalling
complex [35].
Unlike TNFR1, TNFR2 lacks a DD. However it does possess an intra-
cellular TRAF-binding motif, by which it too has the potential to modu-
late inﬂammatory status. The distinct cytoplasmic domains could
account for the differential signalling of the receptors by sTNFα and
mTNFα. It was found that mTNFα was a more potent activator of
TNFR2 than sTNFα and induced distinct biological outcomes [36]. Fur-
ther, activation of TNFR1 was found to stimulate NF-κB expression to a
signiﬁcantly greater extent than TNFR2 [37]. Finally, Scatchard analysis
of ligand binding to TNFR1 and TNFR2 found that the former had a
higher afﬁnity for TNFα [38]. Thus, TNFR1 is considered to be the
more important of the two receptors for the activation of pro-
inﬂammatory signalling pathways.
Importantly, several cytokine receptors have been found to undergo
ectodomain shedding bymembrane-localised proteolytic enzymes. This
process releases a soluble form of the receptor that can have a biological
role such as limiting cytokine availability to other cells, and akin to that
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following ligand binding, terminating the signal by decreasing availabil-
ity of plasma membrane receptors as well as releasing soluble TNFR to
sequester free TNFα [39,40]. The production of soluble TNFR1 has
been described in inﬂammatory conditions [41]. As mentioned above,
TNFR1 forms a trimer prior to ligand binding, which could lead to acti-
vation of signal transduction by bringing together the DD of the recep-
tors. This can be suppressed by the association of the silencer of death
domains (SODD) with the TNFR DD [42]. Following TNFα binding,
SODD disassociates from TNFR, allowing adaptor molecules to be re-
cruited [42]. Thus, there are instrinsic mechanisms to limit TNFR signal-
ling in the absence of ligand, as well as to curtail signalling following
ligand binding.
2.3. Interleukin-6 (IL-6)
The interleukin-6 (IL-6) family are pleiotropic cytokines that include
the members IL-6 itself and IL-11 [43]. IL-6 is expressed by an array of
cells, including mononuclear phagocytes, T cells, B cells, ﬁbroblasts, en-
dothelial cells, keratinocytes, hepatocytes, and bone marrow cells [44].
IL-6 is involved in haematopoiesis, and is critical in the ﬁnal maturation
of B-cells into antibody-producing plasma cells [45], T cell activation,
differentiation and regulation of Th2 and Treg phenotypes [46,47]. It is
also important in the secretion of acute phase proteins by the liver
[48], which it does in cooperation with IL-1 [6]. Previous names for IL-
6 illustrate some of these biological activities, including hepatocyte-stimulating factor (HSF), B-cell stimulatory factor 2 (BSF-2), and B cell
differentiation factor (BCDF). The discovery and cloning of BSF-2 in
1986 [49] was followed by recognition of the fact that these diverse ac-
tivities were due to a single cytokine, renamed IL-6 [45]. The gene
encoding IL-6 wasmapped to chromosome 7 in humans and it encodes
a glycoprotein that ranges in mass from 21 to 28 kDa, depending on the
extent of post-translational modiﬁcation [50].
IL-6 signals through a ligand-binding IL-6 receptor (IL-6R) α chain
(gp80, CD126) and the signal-transducing component gp130 (CD130)
[43]. CD130 is the common signal transducer for several cytokines in
the IL-6 family and is ubiquitously expressed [51], whereas the IL-6R
subunit is typically restricted to lymphocytes and hepatocytes [52]. Fol-
lowing IL-6 binding, the signal is transduced by the gp130 chains to
activate JAK-STAT signalling (Fig. 4). This signalling pathway leads to
phosphorylation of STAT3, a member of the wider STAT family of
transcription factors which are associated with cytokine signalling
(Table 3), and results in STAT3 nuclear translocation and IL-6-
responsive gene expression. In addition to themembrane-bound recep-
tor, a soluble form of IL-6R (sIL-6R) is generated by TACE-mediated
cleavage and can capture circulating IL-6 and make it available to bind
and activate gp130 via a process of trans-signalling [43]. In contrast, a
soluble form of gp130 functions as an anti-inﬂammatory decoy recep-
tor, blocking sIL-6R trans-signalling [53]. More recently, the caspase-
mediated cleavage of gp130 has been found to produce a small,
18 kDa C-terminal fragment and to thereby terminate IL-6 signal trans-
duction, possibly leading to apoptosis [54]. Thus, a common theme of
IL-6R/gp130 complex
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PStat3
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Fig. 4. IL-6 signalling pathway. The cytokine binds to the FIII domains of the IL-6R chains, ultimately activating signal transduction via the gp130 proteins. This leads to recruitment of janus
kinases (JAKs) to the receptor, which phosphorylate the receptor and themselves. This leads to STAT3 phosphorylation and dimerization. Phosphorylated STAT3 dimers translocate to the
nucleus and bind to an IFNγ activation site (GAS) in responsive genes. This leads to the transcription of pro-inﬂammatory genes and intracellular adhesion molecules.
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modulate signalling or produce a soluble ectodomain to bind to circulat-
ing ligands.
3. Chemokine signalling
Pro-inﬂammatory chemokines are produced by cells primarily to re-
cruit leukocytes to the sites of infection or injury. Chemokines induce
integrin expression, such as the β2-intergrin lymphocyte function–as-
sociated antigen (LFA-1), in target leukocytes that act to arrest the
rolling of these cells and favour diapedesis through the endothelium
[55]. Although chemotaxis is the cardinal feature of chemokines, their
physiological role is more complex, with many having additional ho-
meostatic or housekeeping functions in hematopoiesis, initiation of
adaptive immune responses and immune surveillance [56].
Initially chemokines were divided into groups based on having che-
motactic or homeostatic function, but several dual-function chemokinesTable 3
The STAT family of proteins in cytokine signalling.
STAT Cytokine signalling pathway
STAT1 IFNα/βa IFNγa Epidermal growth factor, platelet-derived growth
factor, M-CSF, IL-6, IL-11
STAT2 IFNα/βa IFNλ
STAT3 IL-6 (IL-6 family cytokines, including IL-6, oncostatin M, and LIF)
trigger STAT3 though the gp130 receptor) IL-5, IL-10, epidermal
growth factor, human growth factor
STAT4 IL-12 (essential endogenous mediator of TH1 differentiation)
STAT5A and
STAT5Bb
Prolactin IL-2, IL-3, IL-7, GM-CSF, erythropoietin, thrombopoietin
STAT6 IL-4 (essential endogenous mediator of TH2 differentiation)
a IFNα/β signalling complex (interferon-stimulated gene factor 3) consists of trimers of
STAT1 (alternatively spliced α [p91] or β [p84] peptides), STAT2, and the non-STAT pro-
tein p48. IFNγ signalling complex consists of dimers of STAT1.
b Two distinct genes that are 90% identical.have since been described [55]. To date, 44 chemokines and 23 chemo-
kine receptors have been identiﬁed in the human genome [57]. It is the
expression of particular chemokines, receptors, and adhesionmolecules
that contribute to the selectivemigration and tissue speciﬁcity of leuko-
cytes. Chemokines are a group of small (8–12 kDa) proteins that are
characterised by the presence of three to four conserved cysteine resi-
dues. They can be subdivided into four families based on the positioning
of the N-terminal cysteine residues (Table 4). The C–X–C subfamily is
characterised by the separation of the ﬁrst two cysteines by a variable
amino acid, while in the C–C subfamily the cysteine residues are
adjacent to each other. The majority of the known chemokines are
contained in the CXC and C–C subfamilies but two additional chemokine
subgroups have been described. The third group of chemokines (the C
subfamily) lacks the ﬁrst and third cysteines and thus possesses only a
single cysteine residue in the conserved position. This subfamily includes
the lymphocyte-speciﬁc chemotactic peptide XCL1 (lymphotactin) [58].
A fourth subfamily (CX3C) has the twoN-terminal cysteine residues sep-
arated by three variable amino acids [59]. In humans, this family has only
one member: CX3CL1 (fractalkine), which is unique in possessing a
mucin-like glycosylated stalk that allows it to exist as a soluble or
membrane-bound chemokine [59].
Chemokine signals are transduced through binding to members of
the seven-transmembrane, G protein–coupled receptor (GPCR) super-
family [56], although there is also evidence that other effector pathways
are possible [60]. There is heterogeneity in chemokine receptor expres-
sion in cells and they can formmultiple complexes, such as the demon-
stration that CXCR4 and CCR5 can heterodimerise when stimulated
with their respective ligands [61]. The G proteins associatewith the car-
boxyl terminus of the receptor and signal-induced conformational
changes activates G protein-mediated signalling [60]. In addition,
there are a number of decoy receptors for chemokines that are not
coupled to G proteins and so cannot signal, including: duffy antigen re-
ceptor for chemokines (DARC), D6, and CCX-CKR [62]. Decoy chemo-
kine receptors are generally thought to play a role in dampening the
Table 4
Chemokine families. The most common names for the human ligands are listed. ELR is a
conserved amino acid motif (Glu-Leu-Arg) immediately preceding the ﬁrst cysteine
amino acid in the CXCL chemokine family.
Systematic name
(common name)
Receptor
CC chemokine/receptor family CCL1(I-309) CCR8, R11
CCL2 (MCP-1, MCAF) CCR2
CCL3 (MIP-1α/LD78α) CCR1, R5
CCL3L1 (LD78β) CCR5
CCL4 (MIP-1β) CCR5
CCL4L1 CCR5
CCL4L2 CCR5
CCL5 (RANTES) CCR1, R3, R4, R5
CCL6 (C-10) CCR1, R2, R3
CCL7 (MCP-3) CCR1, R2, R3
CCL8 (MCP-2) CCR1, R2, R5, R11
CCL9 (MRP-2/MIP-1γ) CCR1
CCL10 (MRP-2/MIP-1γ) CCR1
CCL11 (Eotaxin) CCR3
CCL12 (MCP-5) CCR2
CCL13 (MCP-4) CCR1, R2, R3, R11
CCL14 (HCC-1) CCR1
CCL15 (HCC-2, Lkn-1) CCR1, R3
CCL16 (HCC-4, LEC) CCR1
CCL17 (TARC) CCR4
CCL18 (DC-CK1, PARC) Unknown
CCL19 (MIP-3β, ELC) CCR7, R11
CCL20 (MIP-3α, LARC) CCR6
CCL21 (6Ckine, SLC) CCR7, R11
CCL22 (MDC, STCP-1) CCR4
CCL23 (MPIF-1) CCR1
CCL24 (MPIF-2, Eotaxin-2) CCR3
CCL25 (TECK) CCR9, R11
CCL26 (Eotaxin-3) CCR3
CCL27 (CTACK, ILC) CCR2, R3, R10
CCL28 (MEC) CCR3, R10
C chemokine/receptor family XCL1 (Lymphotactin) XCR1
XCL2 (SCM1-b) XCR1
CXC chemokine/receptor family CXCL1 (GROα, MGSA-α) CXCR2 N R1
CXCL2 (GROβ, MGSAβ) CXCR2
CXCL3 (GROγ, MGSAγ) CXCR2
CXCL4 (PF4) CXCR3
CXCL4L1 (PF4V1) CRCR3
CXCL5 (ENA-78) CXCR1, R2
CXCL6 (GCP-2) CXCR1, R2
CXCL7 (NAP-2) CXCR2
CXCL8 (IL-8) CXCR1, R2
CXCL9 (Mig) CXCR3
CXCL10 (IP-10) CXCR3
CXCL11 (I-TAC) CXCR3
CXCL12 (SDF-1α/β) CXCR4, R7
CXCL13 (BLC, BCA-1) CXCR3, R5
CXCL14 (BRAK, bolekine) Unknown
CXCL15 Unknown
CXCL16 (SR-PSOX) CXCR6
CXCL17 (VCC1, DMC) Unknown
CX3C chemokine/receptor family CX3CL1 (Fractalkine) CX3CR1
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recently, this concept has been challenged by the ﬁnding that duffy
antigen receptor for chemokines (DARC) can mediate chemokine
transcytosis, leading to apical retention of the chemokine and enhanced
leukocyte migration across monolayers [62,63].
Chemokines perform a variety of functions aside from chemotaxis,
including T helper cell differentiation and function, as well as angiogen-
esis. Chemokines can have direct effects on T cell differentiation through
direct interactions on the developing cell or indirectly by altering APC
trafﬁcking or cytokine secretion. For example, it was recently found
that the chemokine receptor, CXCR3, was upregulated on CD4+ T
cells and this was associated with cytokine expression and differentia-
tion of these cells to type 1 (Th1) cells [64]. An important role of the
chemokines is in angiogenesis, although this function lies with a sub-
class of the CXC chemokines. The CXC chemokines can be divided intotwo general subgroups (ELR and non-ELR) based upon the presence or
absence of the amino acidmotif (Glu-Leu-Arg) immediately preceeding
the ﬁrst cysteine [65]. The ELR-positive chemokines (CXCL1, CXCL2,
CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8/IL-8) are angiogenic and act
mainly through the CXCR2 receptor [66]. The ELR motif, along with
the CXC residues, is required for receptor activation [66]. By contrast,
the non-ELR chemokines (CXCL4, CXCL9, CXCL10, CXCL11 and
CXCL17) are angiostatic and act mainly through the CXCR3B receptor
[67]. The exception to this is CXCL12, which is a non-ELR chemokine
but is angiogenic and exerts its effects on the vasculature primarily by
binding to CXCR4 and CXCR7 [68]. The role of chemokines thus extends
beyond chemotaxis to include contributions to vascularisation and an-
giogenesis in cancer.
Chemokine release from cells can also trigger the destructive inva-
sion of immune cells into essential tissues and organs. This occurs in
both type 1 and type 2 diabeteswhere glucotoxicity activates pancreatic
β-cell NLRP3 inﬂammasomes [69], thereby driving production and re-
lease of IL-1β [70]. This then acts in an autocrine manner, binding the
β-cell IL1R and triggering the activation of the transcription factor NF-
κB [70]. This results in the synthesis and release of a host of other cyto-
kines and chemokines from islet cells [71]. Thesemolecules trigger inﬁl-
tration of the pancreas by macrophages and other immune cells [72].
Together this toxic cocktail of endogenous and immune cell released cy-
tokines results in the apoptotic destruction of insulin secreting β-cells
[73,74].3.1. Interleukin-8 (IL-8)
Also known as CXCL8, IL-8 is one of the most widely studied
chemokines and is a critical inﬂammatory mediator. It was originally
identiﬁed for its role in chemoattraction of neutrophils, for which it
was named neutrophil chemotactic factor (NCF) and neutrophil activat-
ing protein (NAP-1) [75,76]. The IL-8 genomic structure was ﬁrst
mapped in the late 1980s [77]. The IL-8 protein is 6–8 kDa in molecular
mass and belongs to a subdivision of the CXC chemokines [78]. It acts as
an angiogenic factor in humanmicrovascular endothelial cells [79]. The
main role of IL-8 in inﬂammation is in the recruitment of neutrophils
[80], although it is also responsible for the chemotactic migration and
activation of monocytes, lymphocytes, basophils, and eosinophils at
sites of inﬂammation [75]. IL-8 can be found in either monomeric or di-
meric forms and both are required for neutrophil activation, albeit with
distinct kinetics [81]. Further, the binding of dimers to glycosaminogly-
cans (GAGs) is more efﬁcient and therefore facilitates binding to endo-
thelial cells, as well as binding to the CXCR1/2 on the neutrophils [81].
Indeed, heparinwas found to be the only GAGassociatedwith IL-8 to in-
duce neutrophil chemotaxis [82]. Although IL-8 can bind to both CXCR1
and CXCR2, it has been found that chemotactic signalling is primarily via
CXCR1 [78,80]. Following binding to CXCR1 or CXCR2, a number of in-
tracellular signalling cascades are activated within the target cells to in-
duce chemotaxis and degranulation (Fig. 5). These cascades are initiated
primarily via the activation of intracellular G proteins, resulting in the
dissociation of the proteins from the receptor and separation of the
Gα and Gβγ subunits. The G protein subunits then stimulate enzymes
(adenylate cyclase or phospholipase C) that can activate MAPK signal-
ling and alter gene expression to promote cell survival, proliferation
and inﬂammation. Importantly, the production of 3,4,5-inositol triphos-
phate (IP3) triggers the release of intracellular calcium stores that
stimulate degranulation. Neutrophil granules contain several effector
molecules, such as the antimicrobial proteins myeloperoxidase,
defensins and lysozyme [83]. In addition, IL-8 signalling viaMAPK and
phosphatidylinositol-3 kinase (PI3K) induces the expression of adhe-
sionmolecules such as the integrin,Mac-1, that are required for chemo-
taxis [84]. Thus, IL-8 mediates the recruitment and activation of
neutrophils via complex signallingmechanisms and extracellular adhe-
sion molecules.
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Several diseases have been described in which aberrant or excessive
signalling by cytokines contributes to pathogenesis [85]. For example,
up-regulation of IL-1 and IL-6 has been observed in a variety of chronic
inﬂammatory and autoimmune disorders such as type I diabetes, rheu-
matoid arthritis, lupus nephritis, psoriasis and systemic sclerosis
[86–90]. It is well established that TNFα is directly involved in the pa-
thology of several systemic diseases (Fig. 6), as well as affecting disease
pathology throughmore localised effect. Importantly, appropriate levels
of TNFα are also essential to perform key homeostatic functions,
exerting a variety of effects on normal cell function, including cell prolif-
eration, necrosis and apoptosis [27]. TNFα serves a key function in
orchestrating the inﬂammatory response [31] that includes both sys-
temic and local responses. TNFα actions include triggering the vascular
endothelial cell expression of lipid mediators that promote tissue oede-
ma, as well as leukocyte adhesionmolecules that stimulate immune cell
inﬁltration. For example, the early induction of chemokine expression
and lymphocyte inﬁltration in response to microbial infection is due
to the actions of TNFα [91]. A number of large studies have shown the
efﬁcacy of anti-TNFα therapy in inﬂammatory diseases. Importantly, in-
sight into the central function of TNFα in synovial inﬂammation led to
the development of TNFα blockers, which have proven to be highly ef-
fective therapeutics [92].
Speciﬁc chemokines and their receptors have also been found to be
elevated in the tissues of patients with inﬂammatory conditions
(Table 5). IL-8 can be detected in synovial ﬂuid from patients with var-
ious inﬂammatory rheumatic diseases [93], and mucosal levels of IL-8
are elevated in patientswith active ulcerative colitis [94]. Elevated levels
of CC chemokines, particularly CCL2, CCL3, and CCL5 in the joints ofpatients with rheumatoid arthritis, coincide with the recruitment of
monocytes and T cells into synovial tissues [95,96]. In addition, CCR5,
CCR6, CCR7, CXCR3, CXCR4 and CXCR5 have also been implicated in B-
cell synovial cytokine production and activity [97]. Psoriasis pathophys-
iology is also linked to chemokine-mediated inﬂammation and
Table 5
Chemokines and chemokine receptors implicated in inﬂammatory diseases.
Chemokine/chemokine receptor Disease
CXCR4 WHIM syndrome
CX3CR1, CX3CL1, CXCL1, CXCL8, CXCR2, CCL2 Atherosclerosis
CCL2, CCL5, CCL7, CCL11, CXCL8 Asthma, allergic diseases
CCR5, CXCR3 Rheumatoid arthritis
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inﬁltration of T cells [98]. The differential distribution of chemokine re-
ceptors on different leukocyte types also provides a tool for determining
the role of individual chemokines in particular diseases. Here, the con-
tribution of these bioactive molecules to inﬂammatory diseases and
therapeutic strategies for their modulation will be examined.
5. Inﬂammatory disorders and therapeutic strategies
5.1. Auto-inﬂammatory disorders
The relatively new category of auto-inﬂammatory disorders com-
prises a group of inherited diseases of the innate immune system. The
core group consists of six disorders which are also known as hereditary
recurrent fever syndromes. While auto-inﬂammatory disorders share
similaritieswith autoimmune diseases, they represent a distinct catego-
ry of disorders that are characterised by intense episodes of inﬂamma-
tion that result in fever, rash, or joint swelling. These diseases also
carry the risk of amyloidosis which results in a potentially fatal accumu-
lation of protein in organs.
Themost prevalent auto-inﬂammatorydisorder is FamilialMediterra-
nean fever (FMF), but several other such disorders have been described.
These disorders include: tumour necrosis factor receptor associated peri-
odic syndrome (TRAPS), mevalonate kinase deﬁciencies (MKD), severe
mevalonic aciduria (MA), moderate hyper immunoglobulin D and peri-
odic fever syndrome (HIDS), Muckle Wells syndrome (MWS), familial
cold urticaria (FCU) which is also known as familial cold-associated syn-
drome (FCAS), and neonatal-onset multisystemic inﬂammatory disease
(NOMID) syndrome [99]. Finally, an autoinﬂammatory disorder associ-
ated with deﬁciency of IL-1Ra (DIRA) has been described [100]. All of
these auto-inﬂammatory disorders have a common clinical feature in
intermittent episodes of heightened systemic or local inﬂammation, as
well as a common mechanism in aberrant innate immune system
function. Here, we shall describe FMF, TRAPS, NOMID and DIRA in
more detail, detailing how cytokine and chemokines contribute to the
symptoms of the diseases.
5.1.1. Familial Mediterranean fever (FMF)
FMF is characterised by recurrent attacks of fever and serositis with
signiﬁcant acute-phase inﬂammation [101]. The age of FMF onset is typ-
ically before ﬁve years, with over 90% of patients becoming symptomat-
ic within the ﬁrst two decades of life. The diagnosis of FMF is made
based on the clinical symptoms during a bout of the illness. Typically,
an attack has a sudden onset with high fever and lasts from some
hours to 3–4 days; the frequency varies from once per week to once
every few years. The signs of acute serosal inﬂammation include perito-
nitis (90%), pleuritis (45%), scrotitis (5%) and pericarditis (1%), with
erysipelas-like skin lesions reported in 7–40% of patients. There is also
evidence of increased neutrophil inﬁltration in the affected tissues
[102]. Typical laboratory ﬁndings during an attack include leukocytosis,
an elevated erythrocyte sedimentation rate and increased acute phase
reactants (serum amyloid A, ﬁbrinogen, C-reactive protein) [103–105].
Several studies have now shown that these components are also elevat-
ed between attacks in FMF patients [106–108]. This indicates that
though their overt attacks are self-limited in nature, FMF patients expe-
rience subclinical inﬂammation when asymptomatic.Importantly, proteinuria is observed in FMF patients and is highly
suggestive of amyloidosis. Secondary amyloidosis (AA) is the main
and potentially lethal complication of the disease. In patients with phe-
notype II FMF, secondary amyloidosis (AA) is observed andpatients typ-
ically have two mutations in the FMF-associated gene (Mefv). Recently,
a population study in Turkey identiﬁed 27 allelic variants among 22
patientswith phenotype IIMEFV [109]. Most patientswith overt clinical
disease bear two mutations of MEFV; however, it has been recently
emphasised that in a subset of patients, only one mutation can be
detected [110]. Further to this, some heterozygotes displayed inﬂam-
matory symptoms typical of FMF [111–113]. Given the traditional clas-
siﬁcation of FMF as a recessive disorder, this ﬁnding is somewhat
surprising and the above ﬁndings suggest that FMF could be inherited
as a dominant trait, though with reduced penetrance. The presence of
multiple allelic variants further suggests that inheritance of FMF could
be due to more than oneMefvmutation.
The Mefv gene product, pyrin, is a member of the tripartite motif
family (TRIM20) with a conserved C-terminal PRYSPRY domain in
which several of the common mutations observed in FMF are located
[114]. It is hypothesised that wild-type pyrin acts as a suppressor of in-
ﬂammation and that mutation of pyrin leads to a loss of suppression.
Consistentwith this hypothesis and the aforementioned elevation in in-
ﬂammation in patients, the knockout the Mefv gene locus in a mouse
model and the consequent loss of pyrin expression resulted in elevated
levels of IL-1 [115]. Thus, the complete loss of pyrin would result in the
absence of a normal inhibitor of inﬂammation. However, FMF is
characterised by an array of allelic variations that result in mutations
in pyrin, rather than its complete absence. Thus, the symptoms of FMF
are hypothesised to be due to these mutations rendering pyrin less ef-
fective at inhibiting inﬂammation, with a range of severity depending
upon the givenmutation. However, the data do not rule out the hypoth-
esis that somemutations in pyrin could result in a gain of function such
that the mutant pyrin could actively promote the pro-inﬂammatory
pathway or suppress the anti-inﬂammatory arm. A further aspect of
pyrin's biology could be important in this context, as all of the current
evidence suggests that pyrin functions in the context of large protein
complexes. In such complexes, the inclusion of molecules with reduced
function could potentially compromise complex function.
5.1.2. Tumour necrosis factor receptor-associated periodic syndrome
(TRAPS)
TRAPS is a rare autosomal dominant disease. It was initially called
Familial Hibernian Fever because the ﬁrst recognised cases were from
Hibernia, the name given to Ireland by the Romans [116]. Since
then, cases have been described from Europe and Asia, including
Armenians, Sephardic Jews, Arabic and Japanese [117]. It is one of the
most commonly arising hereditary periodic fevers and is the second
most common globally after FMF, with an age of onset of 3 years
[118]. The disease is characterised by recurrent attacks of fever, abdom-
inal pain, migratory myalgia, rash and periorbital oedema. In addition,
some patients develop secondary systemic amyloidosis, which is poten-
tially fatal [118,119]. The attacks usually continue for several days to
weeks but much shorter attacks have also been observed.
In 1998, two groups of investigators independentlymapped the sus-
ceptibility loci for patients with familial Hibernian Fever and autosomal
dominant familial periodic fever to the same distal region of chromo-
some 12p [120,121]. These data strongly suggested that the same
locuswas responsible for the phenotype expressed in both of these syn-
dromes. Review of existing genomic databases revealed several posi-
tional candidate genes including CD4, LAG-3, CD27, C1R, C1S, and
tumour necrosis factor (TNF) receptor super family 1A (TNFRSF1A). Of
these, TNFRSF1A was particularly attractive in light of the central role
that its protein product, TNFR1, plays in inﬂammation. Consequently,
a collaborative effort was undertaken to sequence TNFRSF1A among af-
fected and unaffected members from seven families with autosomal
dominantly inherited recurrent fever syndromes [122]. Sequence
2572 M.D. Turner et al. / Biochimica et Biophysica Acta 1843 (2014) 2563–2582analysis of the ten exons of TNFRSF1A identiﬁed six different missense
mutations in patients that were not present in controls; ﬁve of these
mutations involved highly-conserved cysteine residues that were
present in all 40 symptomatic patients and in only two asymptomatic
family members. Thus, the discovery of mutations in TNFRSF1A led to
a consolidation of these diseases under the name TRAPS.
There are currently over 90 reported mutations in TNFRSF1A leading
to TRAPS (INFEVERS TRAPS database http://fmf.igh.cnrs.fr/infevers). An
early indication of functional mechanism linked to TRAPS pathophysiol-
ogy came from the demonstration of defective receptor shedding from
peripheral blood mononuclear cells isolated from patients possessing
the C52F mutation in TNFR1 [122]. The situation is not straightforward
however, as multiple modes of TNFR1 trafﬁcking dysfunction have
since been reported [123]. However all are thought to alter activity of
the transcription factor NF-κB (Fig. 7), although distinct differences in
NF-κB subunit activity proﬁles have been reported for some of these
mutations. Speciﬁcally, in addition to p65/p50 heterodimer subunit ac-
tivity, the R92Qmutation has been shown to lead to increased activity of
the NF-κB p50/p50 subunit homodimer [124]. Thus, the low disease
penetrance associated with this mutation could be due to a repressive
function of the p50/p50 homodimer. More recent work has shown
that whilst p65 subunit activity is elevated by different TRAPS muta-
tions, c-Rel subunit activity is also elevated in peripheral blood mono-
nuclear cells isolated from TRAPS patients with F60L and Δ42
mutations [125]. Interestingly, while high p65 activity was associated
with elevated IL-8 secretion, high c-Rel activity increased IL-1β and IL-
12 secretion. Different TRAPS mutations therefore generate distinct
NF-κB family subunit activities and this, in turn, results in the generation
of unique cytokine secretory proﬁles [125]. Thus, it would appear that
the NF-κB p65 and c-Rel subunits function as independent pro-
inﬂammatory mediators in TRAPS, promoting the secretion of differentD
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Since the discovery that TNFRSF1A gene mutations drive TRAPS pa-
thology a major area of clinical focus has revolved around development
of anti-TNFα biologics. Etanercept (Enbrel®; manufactured by Pﬁzer
Inc.), a chimeric fusion protein coupling soluble TNFR2 to the IgG1 con-
stant region, was the ﬁrst anti-TNFα drug successfully used to treat
TRAPS patients. Although relativelywell tolerated, etanercept is howev-
er ineffective in somepatients [126] and in others becomes less effective
with repeat doses [127]. Inﬂiximab (Remicade®, manufactured by
Janssen Biotech, Inc.), a chimeric anti-TNF monoclonal antibody, has
also been administered to patients with TRAPS. However not only are
there a number of potentially dangerous side effects to the drug, but cer-
tain TRAPSmutations are actually associatedwith an acute inﬂammato-
ry response to inﬂiximab, most likely due to constitutive signalling
resulting from failure to remove inﬂiximab-bound TNF/TNFRI from the
cell surface of cells of peripheral blood mononuclear cells where the
TRAPS-associated mutation in TNFRSF1A is associated with a shedding
defect [128].
TNFRSF1A mutation and downstream NF-κB activation result in in-
creased levels of pro-inﬂammatory cytokines, including IL-1β, in both
serum and peripheral mononuclear cells of TRAPS patients [125,129].
The recombinant human IL-1R1 antagonist, anakinra (Kineret®;
manufactured by Swedish Orphan Biovitrum), has therefore been ad-
ministered to TRAPS patients in an attempt to reduce inﬂammatory ep-
isodes. Initial ﬁndings indicate sustained beneﬁcial action of this drug in
the treatment of TRAPS [130,131]. However, as with all anti-cytokine
therapies care will need to be taken to investigate potentially damaging
effects of repeated administration. Indeed, it should be noted that low
concentrations of IL-1β actually have a positive physiological effect on
proliferation of certain cell types, such as pancreatic β-cells, and thatD
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tion and secretory function in these cells [132].
5.1.3. Neonatal onset multisystem inﬂammatory disease (NOMID)
NOMID, also known as chronic infantile neurologic cutaneous artic-
ular (CINCA) syndrome, belongs to the cryopyrin-associated periodic
syndromes (CAPS). It affects numerous organs and body systems, in-
cluding the skin, joints, eyes, and the CNS. For most children, the ﬁrst
sign of the disease is a rash that develops within the ﬁrst six weeks of
life. Other problems can follow, including fever, meningitis, joint dam-
age, vision and hearing loss and mental retardation. The disease is the
most severe CAPS disorder and frequently results in death in affected
children [133]. While the mechanism of NOMID is not completely un-
derstood, research has revealed mutations in the NLRP3 (NLR family
pyrin domain 3) gene (formerly known as CIAS1) in approximately
60% of patients with the disease [134]. NLRP3 encodes cryopyrin,
which combines with caspase-1 and ASC to form the inﬂammasome
complex that cleaves pro-IL-1β to generate its mature form [135].
These mutations typically result in excessive secretion of IL-1β [136,
137]. Thus, patients with NOMID usually respond well to anakinra,
resulting in marked improvement both in symptoms and the underly-
ing inﬂammation. Likewise, other patients with CAPS disorders show
improved symptoms with anakinra [138–140].
The short half-life of anakinra necessitates daily injections and injec-
tion site reactions are commonly observed [138–141]. Newer therapeu-
tics with improved pharmacokinetics and tolerance have been
developed. Rilonacept (Arcalyst™; Regeneron Pharmaceuticals) is an
artiﬁcial molecule that contains the ligand-binding portions of both IL-
1R1 and IL-1AcP fused to a dimeric molecule containing the Fc segment
of hIgG1 (human immunoglobulin G1) [142]. It thus acts by binding to
IL-1 with an afﬁnity at least 100-fold higher than that of the native IL-
1R complex, thereby preventing IL-1 binding to cell surface receptors
[142]. In contrast to anakinra, rilonacept has a half-life of approximately
seven days and thus is administered once weekly [143]. Rilonacept has
been approved by the FDA for the treatment of CAPS and it has proven
very effective and safe in a small open-label pilot study patients with
FCAS and MWS [144,145]. In addition to improving symptoms of the
disease, rilonacept also reduced serum levels of serum amyloid A
(SAA) [143,145]. The latter is of great importance given that high
serum levels of SAA are directly related to the risk of developing second-
ary amyloidosis [108], the main cause of renal insufﬁciency in these pa-
tients. Injection site reactions and upper respiratory tract infections
were the two most commonly observed adverse events in patients
treated with rilonacept [143].
A third IL-1 blocker, themonoclonal human anti-IL-1β canakinumab
(Ilaris®, manufactured by Novartis Pharmaceuticals), was used in pa-
tients with CAPS in one small study [146] and in a randomised
placebo-control clinical trial [147]. Canakinumabwas administered sub-
cutaneously once every eight weeks and induced a remarkable clinical
response with normalisation of SAA and C-reactive protein levels
[147]. During the treatment period, only two adverse events were ob-
served – a case of urosepsis and an episode of vertigo [147].
5.1.4. Deﬁciency of interleukin-1 receptor antagonist (DIRA)
DIRA was recently reported as a new autosomal recessive
autoinﬂammatory disease caused by mutations of IL1RN, the gene
encoding the IL-1 receptor antagonist, with prominent involvement of
skin and bone [100]. Children with this disorder display a constellation
of serious and potentially fatal symptoms, including swelling of bone
tissue, bone pain and deformity, inﬂammation of the periosteum and a
rash that can span from small individual pustules to extensive
pustulosis that covers most of the patient's body. Most of the children
begin to have symptoms from birth to 2 weeks of age. Although it has
only recently been described, there is evidence fromprevious case stud-
ies that could be describing DIRA, with severe infantile chronic multifo-
cal osteomyelitis and pustulosis [148]. In the absence of functional IL-1Ra, patients cannot control systemic inﬂammation caused by IL-1 sig-
nalling [149]. Although mutations that cause DIRA are rare there are
nonetheless hotspots, with for instance 2.5% of the population of north-
west Puerto Rico being carriers [149]. Since DIRA is recessively
inherited, these data suggest that it may be present in about 1 in 6,300
births in this population. Mutations may also be more common in indi-
viduals of Dutch descent. Given the basis of the disease in the absence of
IL-1Ra, it is not surprising that the recombinant IL-1Ra drug, anakinra,
has been successful in treating the symptoms of DIRA.
5.2. Pro-inﬂammatory disorders
5.2.1. Inﬂammatory bowel diseases
Inﬂammatory bowel diseases (IBD), including Crohn's disease (CD)
and ulcerative colitis (UC), are characterised by chronic, self-destructive
inﬂammation of the gastrointestinal tract [150]. In both UC and CD,
leukocyte inﬁltration into the intestine is fundamental to disease devel-
opment and progression, with chemokines and their receptors mediat-
ing tissue-speciﬁc and cell type-selective trafﬁcking of leukocytes [151].
Several chemokine pathways have been identiﬁed as being central to
the physiopathology of IBD, including the CCL20–CCR6 and CCL25–
CCR9 ligand/receptor combinations [152]. Recently, the selective re-
moval of leukocytes expressing CCR9 by using CCL25 as bait resulted
in substantial improvement in clinical symptoms in IBD [153]. In addi-
tion, the homeostatic and inﬂammatory roles of the CX3CL1–CX3CR1
and CXCL10–CXCR3 pathways offer promising molecular targets for
therapeutic intervention [152]. There is also evidence of cytokine acti-
vation in the mucosal immune system [154,155], with increased levels
of the proinﬂammatory cytokines IL-1, IL-6, IL-8, and TNFα. Based on
these observations a rationale for anti-TNFα and other anti-cytokine
therapywas deﬁned, and clinical studies have led to somepromising re-
sults [156–159]. A number of large studies have also shown the efﬁcacy
of TNFR and anti-TNFα therapy in RA and Crohn's disease [160–163].
5.2.2. Allergic diseases and asthma
Aberrant regulation of chemokine expression has been implicated in
a number of diseases including allergy and asthma (Table 5). Inﬂamma-
tion is also a key factor in asthma, in which the chemokine CCL11
(eotaxin) and its receptor, CCR3, contribute to the recruitment of eosin-
ophils to the lung [164]. Increased chemokine levels have been ob-
served in asthmatic patient bronchoalveolar lavage and biopsy
samples [165,166], including CCL2, CCL3, CCL5, CCL7, CCL11, CCL13,
CCL24, /IL-8, and CXCL10. In addition, murine models of asthma have
implicated chemokine induction of AHR and cellular emigration
through CCL2, CCL5, CCL11, CXCL10, and CXCL12 in airway inﬂamma-
tion [167,168]. Furthermore, the chemokine CCL11 (eotaxin) and its re-
ceptor, CCR3, contribute to the recruitment of eosinophils to the lung
[164].
The C–C chemokine family has been extensively studied in allergic
diseases because of their ability to recruit eosinophils, T cells, andmono-
cytes to regions of inﬂammation. CCL5 and CCL11 are the most impor-
tant eosinophil chemoattractants in allergic inﬂammation [169]. Aside
from production by eosinophils, macrophages, mast cells, and T cells,
CCL5 and CCL11 are produced by structural cells of the airway, including
airway smooth muscle and ﬁbroblasts. In addition to lymphoid tissue,
nasal epithelial cells express CCL17 (TARC), and expression of this che-
mokine and its receptor, CCR4, was higher in patients with allergic rhi-
nitis compared with that seen in nonallergic control subjects. Both IL-4
and IL-13 promote CCL17 expression, leading to a Th2 response [170].
This is relevant in allergic bronchopulmonary aspergillosis (ABPA), in
which increased serum levels of CCL17 predict ABPA exacerbations bet-
ter than IgE levels [171]. CCL17 levels might also serve as a marker of
ABPA in patients with cystic ﬁbrosis [172].
IL8 is derived primarily from mononuclear phagocytes, endothelial
and epithelial cells, but is also produced by T cells, eosinophils, neutro-
phils, ﬁbroblasts, keratinocytes, hepatocytes, and chondrocytes. IL8
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Onamolar basis, IL8 is one of themost potent chemoattractants for neu-
trophils in addition to stimulating the neutrophil respiratory burst and
adherence to endothelial cells through CXCR1 [174]. However, a num-
ber of additional chemokines also contribute to allergic inﬂammation,
with different Th cell responses and temporal contributions reﬂecting
a complex series of interactions. For example in asthmatic lungs
CXCL10 and CXCL13 are induced at different times after allergen expo-
sure, with CXCL10 produced in early phases, and CXCL13 only induced
after secondary and subsequent exposures. [175]. This likely reﬂects
the cellular sources of these cytokines, with airway epithelial cells pro-
ducing CXCL10, whereas CXCL13 is produced by Th17, but not Th1 or
Th2, cells. It is thus tempting to speculate that Th17 cells might play a
role in asthma in later exposures after the allergic phenotype has al-
ready been established. T cell subsets that might have regulatory activ-
ity are being identiﬁed, and chemokines and their receptors appear to
have important roles in mediating activity and migration of these
cells. Among CD4+CD25+Foxp3+ nTreg cells, there appears to be at
least 2 subgroups that can be distinguished based on CCR6 expression.
Those that are high in CCR6 seem to have regulatory activity, whereas
those low in CCR6 secrete Th2 cytokines on stimulation with bacterial
superantigen [176]. Another group has demonstrated low levels of
XCR1 on the surface of CD4+CD25hiCD127low Treg cells isolated from
allergic asthmatic subjects compared with those from healthy control
subject [177]. Although in a relatively early stage, this emerging ﬁeld
of chemokine response and expression by Treg cells will hopefully clar-
ify many of the questions about how these cells work.
5.2.3. Behçet's disease
Behçet's disease (BD) is a multi-centre inﬂammatory disease, with
symptoms including oral and genital canker sores or ulcers and ocular
inﬂammation. In some patients, the disease also results in arthritis,
skin problems, and inﬂammation of the digestive tract, brain, and spinal
cord [178]. Behçet's disease is common in the Middle East, Asia, and
Japan, although it is rare in the United States. In Middle Eastern and
Asian countries, the disorder affects more men than women, while in
the United States the opposite is true. Behçet's disease tends to develop
in patients in their twenties or thirties. Whilst the precise cause of
Behçet's disease is currently unknown, themajority of symptoms result
from inﬂammation of blood vessels. Serum levels of several cytokines
are elevated, including IL-1, IL-4, IL-6, IL-8, IL-10, IL-13, IL-18 and
TNFα [179,180], while IL-15 levels in the cerebral spinal ﬂuid (CSF)
were higher in patientswith BD of patients than in patients in remission
or healthy controls [181]. Corticosteroids and immunosuppressive
drugs are commonly used to treat the disease.
It has been demonstrated that there is a polarisation of the T cell re-
sponse in BD towards the production of type I cytokines (a Th1 re-
sponse) [182,183]. Previous work showed a preponderance of the
CXCR3+ CD3+ subset of Th1 cells in BD [183]. The γδ T cells have a
non-redundant role in immune responses, particularly to bacterial in-
fections. They also make potent anti-tumour responses and have been
implicated in various autoimmune diseases. Patients with BD have in-
creased numbers of γδ T cells in circulation and in mucosal lesions
[184]. In one study there was an elevated number of the Vγ9Vδ2 subset
of γδ T cells in the intraocularﬂuid of BD patients with uveitis [185]. The
γδ T cells in BD have an activated phenotype, expressing markers such
as CD25, CD29 and CD69, and producing pro-inﬂammatory cytokines,
such as IFN-γ, TNFα and IL-8 [182]. Further, the γδ T cells from BD pa-
tients proliferate in response to mycobacterial HSP-derived peptides
and in response to products from microorganisms in oral ulcers [184,
186]. Importantly, γδ T cells also proliferate in the presence of IL-12
and it has been demonstrated that serum levels of IL-12 are increased
in BD [187]. In addition to T cells, it is likely that antigen-presenting
cells (APCs) contribute to BD by the cytokines they secrete, including
IL-12 and IL-18; the former contributes to T cell activation, while the
latter has been shown to stimulate neutrophils [182]. Indeed, thecombined effects of APCs andγδ T cells are thought to lead to neutrophil
hyperactivity [182]. Neutrophils are hyperactive in BD, with increased
chemotaxis, phagocytosis, superoxide production andmyeloperoxidase
expression, aswell as producing several cytokines, including IL-12 [188,
189]. Given the aforementioned responsiveness of the γδ T cells in BD,
this additional secretion of IL-12 by neutrophils is likely to exacerbate
the symptoms.
5.2.4. Rheumatoid arthritis (RA)
Rheumatoid arthritis is an autoimmune disease characterised by the
presence of autoantibodies (rheumatoid factors) and chronic inﬂamma-
tion that leads to tissue destruction [92]. A role for dysregulation of cy-
tokines in the synovial tissues was identiﬁed early on as a potential
factor in RA pathogenesis [190]. This led to the discovery that anti-
TNFα antibodies inhibited the production of IL-1 in these tissues and
the suggestion that TNFα induced IL-1 production by synovial cells
[191]. At around the same time elevation in TNFα was linked to the
pathogenesis of polyarthritis in mice [192]. Importantly, this study
also demonstrated that administration of an anti-TNFαmonoclonal an-
tibody prevented development of the disease in these animals. Subse-
quently the expression of both TNFR1 and TNFR2 was found to be
upregulated in synovial tissues of patients with RA [193]. Combined
with the prior observations, this evidence established TNFα as the key
pathogenic cytokine in RA.
Chimeric anti-TNFαmonoclonal antibodieswere developed for clin-
ical trials in humans and found to be highly successful in improving
markers of RA in patients [194]. The chimeric monoclonal antibody,
inﬂiximab, was subsequently approved for use in the treatment of RA
[92]. In addition, other monoclonal anti-TNFα therapeutics have been
developed with various modiﬁcations to improve efﬁcacy or safety,
such as the recombinant, fully-human antibody adalimumab [92]. In-
tensive research on the role played by cytokines in RA has thus lead to
advances in therapeutics, particularly the development of novel anti-
TNFα therapies.
The BeSt trial revealed that several patients with early RA receiving
inﬂiximab (TNFα blockade) with methotrexate were able to stop
treatment (if they reached a low disease activity state without
subsequent disease ﬂare) [195]. Remarkably, a proportion of patients
remained in clinical remission for up to 4 years, with a small number
(14%) being drug-free (i.e., not being treated with disease-modifying
anti-rheumatic drugs (DMARDs)) [195]. Currently, the outcome of
such trials is leading clinicians to question whether treatment with
anti-TNFα therapeutics can eventually lead to remission and the ability
to discontinue the use of such agents in patients who have achieved re-
mission [196]. For some patients on adlimubab or inﬂiximabwithmeth-
otrexate who have been in remission for an extended period of time,
discontinuation of the treatment could be feasible [196].
While TNFα clearly has a pivotal role in RA, several other cytokines
are present in the synovial tissue and could also contribute to pathogen-
esis. Among these is IL-6, which signals via a JAK-STAT pathway. Recent-
ly, an inhibitor of JAK signalling has been developed and this is now
approved for use in the treatment of moderate to severe RA. The small
molecule JAK inhibitor, tofacitinib (Xeljanz;® manufactured by Pﬁzer
Inc.), is to be used initially as a second-line therapy for patients who
fail to respond to methotrexate or anti-TNFα biologicals [197]. Thus
the early success of TNFα inhibition is serving as amodel for developing
other treatments of RA that target cytokine signalling pathway compo-
nents to limit inﬂammation.
Whilst blockade of TNFα is often beneﬁcial in the short-term, it is not
curative, and its effects are often only partial and non-responsiveness is
also common. Moreover, loss of effect has been observed. Despite
advances in the treatment of RA, particularly the anti-cytokine thera-
peutics, it is still a formidable clinical problem with the risk of progres-
sive articular damage (radiographic progression), functional decline
and comorbidities remain formany patients. Crucially, there is as yet lit-
tle evidence that we can re-establish immunologic tolerance and hence
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icities remain idiosyncratic, with few reliable biomarkers for prognostic
or therapeutic purposes having been identiﬁed thus far. One therapeutic
strategy would be to evaluate and target speciﬁc cytokines present at
particular stages of the disease. Alternatively, the combination of anti-
TNFα therapeutics with other drugs, such as the new JAK inhibitor
[197], could result in improved clinical outcomes.
5.3. Neurological disorders involving inﬂammation
Inﬂammation is a process that is implicated in the onset of various
neurodegenerative diseases. Over the last decade increasing knowledge
has emerged on the role of cytokines in brain physiology. As for other
organs, excessive cytokine expression in the brain is harmful and has
been associatedwith neurological disorders, including both Alzheimer's
disease (AD) and Parkinson's disease (PD). As will be discussed below,
these complex neurodegenerative disorders are associatedwith compli-
cated, multifactorial changes in inﬂammatory molecules.
5.3.1. Alzheimer's disease
Themolecular and cellularmechanisms responsible for the aetiology
and pathogenesis of AD have been widely studied and several hypothe-
ses advanced.While thehypotheses differ in the initiating trigger for the
disease, inﬂammation within the brain is thought to play a pivotal role.
Studies suggest that peripheral infection or inﬂammation could also af-
fect the inﬂammatory state of the central nervous system (CNS). This in-
cludes chronic periodontitis, which has been associated with several
systemic diseases such as AD [198]. Other hypotheses include the out-
come of viral infection of the CNS triggering either a chronic inﬂamma-
tory state or even inducing autoimmune dysfunction within the brain.
Chronic infection with herpes simplex virus type 1 (HSV1) and its reac-
tivation from latency are associatedwith AD pathology [199,200]. In ad-
dition, activation of TLRs on microglia by bacterial infections in the CNS
can contribute to neuronal cell death and AD symptoms [201]. Thus the
initiating trigger could be either localised infection in, or the impact of
peripheral inﬂammation on, the CNS.
The pathology of AD is characterised by proteinaceous lesionswithin
the brain as well as by neuronal loss. Pathological lesions such as amy-
loid plaques containing the cleaved Aβ protein and neuroﬁbrillary tan-
gles containing tau protein are frequently observed in the brains of AD
patients [202]. Emerging evidence suggests that inﬂammatory re-
sponses contribute to the progression of AD, accelerating the course of
the disease. Under the inﬂuence of IL-1 originating from activated
microglia, astrocytes in neurite plaques were found to over-express
the neurotrophic calcium binding protein, S100B [203]. Over-
expression of S100B has been found to accelerate AD-like pathology in
a transgenic mouse model [204]. Additionally, the expression of α1-
antichymotrypsin (ACT), a protein associated with amyloid plaques in
AD [205], was found to increase in response to the treatment of astro-
cytes with IL-1 and IL-6 [206]. AD brains were also found to have high
levels of nitrous oxide synthase (NOS)-positive astrocytes compared
to controls [207], suggesting increased production of NO in the AD
brain. In support of this, Aβ peptides induced astrocytes to produce IL-
1β, NOSmRNA andNO [208].More recently, a feed-forwardmechanism
was proposed, whereby Aβ activation of astrocytes results in the pro-
duction of APP and the BACE enzyme responsible for Aβ cleavage, gen-
erating more peptides that contribute to plaque formation [209].
Regardless of the cause, inﬂammation in the CNS involves the activa-
tion ofmicroglia and astrocytes, resulting in the release of inﬂammatory
mediators such as cytokines, chemokines, neurotransmitters and reac-
tive oxygen species (ROS) [210]. Microglia are particularly important
in the CNS immune response and are generally thought to be neuropro-
tective, with resting microglia becoming activated in the presence of
pathogens, damaged cells and cell debris, and functioning to clear per-
ceived danger signals to protect neurons [211]. However there is also
evidence that microglia can have neurotoxic effects in the brain [212],likely via the release of potent pro-inﬂammatory molecules [213] and
other immunomodulatory molecules which lead to the recruitment of
monocytes and lymphocytes through the blood-brain barrier (BBB)
[214,215]. This leads to activation of additional microglia and also pro-
motes their proliferation, thereby amplifying the release of inﬂammato-
ry factors [216].
Soluble Aβ oligomers are thought to activate microglia via stimula-
tion of innate immune receptors [212], thus triggering the above-
mentioned inﬂammatory process. Amyloid plaques are also thought to
attract and activate microglia, leading to clustering of microglia around
Aβ deposit sites in the brain [217]. Microglia also express scavenger re-
ceptors that mediate adhesion of the microglia to Aβ ﬁbril-coated sur-
faces, thus leading to ROS secretion and cell immobilisation [218]; the
secretion of ROS is particularly associated with neuronal damage since
it can cause lipid and protein cross-linking and consequent loss of
function. Microglia activated by Aβ secrete elevated levels of pro-
inﬂammatory cytokines and chemokines [213,219], the latter enhanc-
ing the ability of peripheral monocytes to pass through the BBB [220].
Microglia exposed to Aβ can also be activated through receptors for ad-
vanced glycation end products (RAGE) and macrophage colony-
stimulating factor (M-CSF) [221]. M-CSF induces furthermicroglial che-
motaxis towards Aβ, and also increasedmacrophage scavenger receptor
expression. Interestingly, removal of M-CSF from cultures resulted in
apoptosis of microglia [222], whilst treatment of microglia with anti-
RAGE F(ab′)2 resulted in decreased secretion of M-CSF and reduced
chemotaxis towards Aβ [221]. This would seem to suggest that thera-
peutic strategies that employ similar rationales might offer patients
with AD an improved prognosis.
The presence of microglia around Aβ plaques is not necessarily det-
rimental however, as M-CSF induction of microglia to the parenchyma
of Swedish β-amyloid precursor protein (APPSwe)/PS1 transgenic
mice has been shown to decrease the number of Aβ deposits and pre-
vent cognitive loss compared to vehicle controls [223]. These ﬁndings
support the view that M-CSF stimulates and attracts bone marrow-
derived microglia into the CNS, and induces neuroprotective functions
in microglia leading to Aβ clearance. However microglia are not the
only cells in the CNS to internalise Aβ, and the uptake of these peptides
by astrocytes and neurons also likely contributes to AD pathology. As-
trocytes contribute to Aβ clearance and degradation, as well as provid-
ing trophic support to neurons and forming a protective barrier
between Aβ deposits and neurons [224,225]. Astrocytes have been
found to cluster around Aβ deposits and these deposits are thought to
activate inﬂammatory signalling in astrocytes [212]. Likewise, in a
mouse model of AD, astrocytes were found to degrade Aβ (1–42) pep-
tides in vitro and in situ, thereby clearing the Aβ deposits in what is
hypothesised to be a protective housekeeping function of these cells
[224]. However, their tendency to release pro-inﬂammatory molecules
is thought to stimulate and even accelerate the progression of AD. Astro-
cytes activated byAβ produce chemokines, cytokines, and ROS thatmay
result in neuronal damage [226,227]. Importantly, it has been found that
neurons can also take up Aβ peptides and the internalisation of Aβ by
neurons is considered to be one of the earliest signs of AD [228]. This
ﬁnding is consistent with the results of previous studies which have
shown that the Aβ obtained from phagocytosed neurons accumulates
within astrocytes and that amyloid plaques form when these Aβ-
burdened astrocytes die [229]. Chemokines released by astrocytes
also attract microglia, thus further adding to the complexity of AD
pathogenesis.
Finally, neurons themselves appear to contribute to the production
of neuroinﬂammatory products in AD, although they were traditionally
believed to be passive bystanders in neuroinﬂammation. Neurons pro-
duce several chemokines and cytokines including IL-1 [230,231], IL-6
[232] and TNFα [228]. Neuronal chemokines in particular act as mes-
sengers between neurons and glial cells [233,234]; the secretion of
CD22 by neurons inhibits pro-inﬂammatory cytokine production in mi-
croglia [235]. In addition, neurons are able to serve as a source of
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loid P [239], cyclooxygenase (COX)-2-derived prostanoids [220,
240–242] and inducible NOS [243]. Thus, the secretion of pro-
inﬂammatory molecules by neurons could serve to enhance the inﬂam-
mation in the brain due to the response of glial cells to the Aβ-
containing plaques, thereby contributing to the pathogenesis of AD.
5.3.2. Parkinson's disease
PD is the most common neurodegenerative movement disorder
[244], with symptoms including resting tremor, slowed movement,
postural instability andmuscle rigidity, aswell as non-motor symptoms
[245,246]. It is an age-dependent disorder characterised by the progres-
sive degeneration of dopaminergic (DA) neurons in the substantia nigra
(SN). In addition, inclusions called Lewy bodies (LBs), which are com-
posed of α-synuclein and ubiquitinated proteins, are found within the
remaining SN neurons [247]. There is debate aboutwhether LBs directly
cause neuronal death or perhaps sequester smaller neurotoxic protein
aggregates to preserve neuronal viability [248–250]. The motor symp-
toms can be treated with DA therapeutics; however, the effectiveness
of these agents diminishes as the severity of the clinical symptoms in-
creases due to progression of the underlying neurodegeneration [251].
The recent identiﬁcation of mutations in several genes linked to rare
inherited forms of PD has led to speculation that these mutations
promote inclusion formation, ubiquitin–proteosome system (UPS) dys-
function and nigral cell loss, although the precise molecular mecha-
nisms are unclear and the pathology in humans and animal models
bearing these mutations is highly variable [252,253]. Nevertheless, re-
cent studies of transgenic animals with mutations linked to Parkinson-
ism, as well as neurotoxin- and virus-based animal models of PD, have
provided valuable insight into potential pathogenicmechanisms involv-
ing neuroinﬂammation. Human clinical imaging, post-mortem exami-
nations and epidemiological studies have recently highlighted the role
of neuroinﬂammation in PD and raise the interesting possibility that
chronic inﬂammation may lead to symptoms of PD [254]. There has re-
cently been signiﬁcant interest in developing novel anti-inﬂammatory
agents that may help prevent or ameliorate CNS inﬂammation [255].
In this section, we will mention a few targets the modulation of which
has yielded promising results which may be translatable to the clinic
in the future.
The presence of activated microglial cells and elevated levels of
several pro-inﬂammatory cytokines are evident in post-mortem exam-
inations of the SN [256,257]. An emerging area of pre-clinical investiga-
tion involves development of strategies to inhibit the glial reaction and
to target pro-inﬂammatory cytokines [258–260]. IL-1β levels have been
reported to increase rapidly after administration of LPS into the SN in
mice and neuroprotection can be achieved by administering an anti-
IL-1β neutralising antibody [261,262]. In the case of TNFα, a rat model
of PD found that inhibition of TNFα prevented DA neuronal cell
death. The use of a recombinant dominant negative TNFα inhibitor,
XENP345, reduced neurotoxin- and endotoxin-induced DA neuronal
death by approximately 50% [263]. In short, it is clear that targeting spe-
ciﬁc inﬂammatory mediators has been a valuable approach to establish
the extent to which the various factors implicated in PD pathogenesis
contribute to loss of DA neurons in animal models. However, due to
the complexity of the human disease and the interactions of inﬂamma-
tory pathways, design of a successful intervention will very likely re-
quire a multi-target approach during the earliest stages of PD.
This complexity of PD pathogenesis is exempliﬁed in the role of NF-
κB activation. Although numerous studies from animal models support
a role for the NF-κB pathway in preventing neuronal death induced by
oxidative stress, excitotoxicity, ischemia, or glucose deprivation [264,
265], there is also evidence supporting a dual role of NF-κB in neurode-
generative diseases. Speciﬁcally, activation of NF-κB in neurons general-
ly promotes their survival, whereas NF-κB mediates proliferation
and activation of glial cells some of which may promote pathological
inﬂammatory processes [264,266,267]. Nuclear translocation of thetransactivating subunit, NF-κB RelA (p65), has been reported to be 70-
fold greater in the SN of PD patients compared age-matched healthy
controls [268]. A relationship between enhanced nuclear translocation
of NF-κB and oxidative stress in DA neurons of PD patients is supported
by in vivo studies in which 6-OHDA-induced oxidative stress in rat DA
neuronswasmediated by an NF-κB-dependent p53-signalling pathway
[269]. Indeed, therapeutic agents for PD that are designed to inhibit NF-
κB activation have been described [256]. The NF-κB essential modulator
(NEMO)-binding domain (NBD) peptides, which inhibit the activation
of NF-κB signalling, have been shown to attenuate the glial response
and MPTP-induced nigral degeneration [270]. Similarly, the synthetic
triterpenoid CDDO-Me, a potent activator of the Nrf2 anti-oxidant path-
way and an inhibitor of NF-κB, attenuates the production of TNFα and
other glial-derived inﬂammatory mediators, thereby reducing the neu-
rotoxicity of activatedmicroglial cultures on DA neuron-like cells [271].
Further, the brain-permeablemethyl amide derivative (CDDO-MA)was
recently shown to afford neuroprotection in vivo against MPTP and 6-
OHDA-induced nigral degeneration in mice and rats [272]. Thus, there
is evidence from in vivo pharmacological studies showing that the inhibi-
tion of oxidant-mediated apoptogenic transduction pathways and NF-κB
activation protects against DA neuronal loss, providing support for a link
between oxidative stress and inﬂammation in PD pathogenesis [273].
Numerous therapeutic agents used to treat inﬂammation or for im-
munosuppression have been found to ameliorate markers of PD. The
immunosuppresants, cyclosporine A and FK-506 (tacrolimus), the
non-immunosuppressant FK-506 derivatives (immunophilin ligands
including pentoxifylline), as well as the non-selective COX-2 inhibitor
sodium salicylate, have all shown neuroprotective activity in either
MPTP-induced nigral injury or the 6-OHDA rat model of PD
[274–276]. Despite this, clinical trials of immunophilin ligands in PD
patients have had limited success [277], possibly due to the advanced
nature of the disease in the patient cohort. Similarly, the glucocorticoid
dexamethasone was protective against both MPTP and intranigral LPS-
induced cell death [278,279]. The semi-synthetic second generation
tetracycline antibiotic derivative minocycline, which has anti-
inﬂammatory properties and readily crosses the BBB, has been investi-
gated in rodent and non-human primate models of PD with mixed out-
comes. In some studies it was shown to be neuroprotective against
MPTP-, LPS- and 6-OHDA-induced nigral DA neuron loss [280–283],
while in others it exacerbated the effects of MPTP in rodents and non-
humanprimates [284,285]. The reason for these discrepancies is unclear
but it could be due to differences in dosing and timing of the interven-
tion regimen. Nevertheless, because minocycline is well-tolerated in
humans, it was tested in a randomised, double-blind, futility clinical
trial in patients with early PD. The recommendation at the completion
of Phase II was for advancement to Phase III clinical trials to determine
ifminocycline could alter long-term progression of PD [286]. The results
of this study suggest that minocycline has a good safety proﬁle and that
it should be tested next in Phase III trials, although no such trial is on re-
cord. In part, this could be due to concerns over theworsening of symp-
toms observed with minocycline in the treatment of amylotrophic
lateral sclerosis (ALS) [287]. Chemical modiﬁcation of minocycline
using structure–activity relationship analysis is being used to develop
safer and more efﬁcacious versions of the drug that can protect nigral
DA neurons at low doses [288].
Other compounds with anti-inﬂammatory actions that have been
shown to rescue nigral DA neurons from a variety of neurotoxic insults
such as LPS and MPTP include vasoactive intestinal peptide (VIP) [289,
290], the polyphenolic ﬂavanoid silymarin [291], the NMDA receptor
antagonist dextromethorphan [292], and agonists of peroxisome
proliferator-activated receptor-γ (PPARγ) [293]. Finally, the use of cer-
tain steroids such as allopregnenalone has been found to protect against
DA neuron loss in rodent models [294,295], although these agents
might be unsuitable for long-term use in humans.
Other agents that have non-immune primary targets have been
found to ameliorate PD symptoms by immunomodulatorymechanisms.
2577M.D. Turner et al. / Biochimica et Biophysica Acta 1843 (2014) 2563–2582The selective iNOS inhibitors S-methylisothiourea and L-N(G)-
nitroarginine were shown to exert neuroprotective effects on DA neu-
rons in rats against LPS [296–299], suggesting that free radical scaven-
gers or iNOS inhibitors may have potential therapeutic effects in PD.
Copolymer-1 (Cop-1) immunisation, which has been used effectively
in patients with chronic neuroinﬂammatory disease such as relapsing
remitting MS, has recently been shown to have neuroprotective effects
in the nigrostriatal pathway against MPTP by several immunomodula-
tory mechanisms, including promotion of CD4+ T cell accumulation
within the SN, suppression of microglial activation and increased local
expression of the potent DA neuron survival factor GDNF [300,301]. In-
terestingly, immunomodulatory effects have also been described in vitro
and in animalmodels treatedwith themonoamine oxidase B (MAO) in-
hibitor drugs pargyline and selegiline (Deprenyl) [302,303]. In summa-
ry, there have been numerous attempts made to repurpose or develop
new immunomodulatory drugs and therapeutic immunisation to treat
neurological diseases and control neuroinﬂammatory responses has
emerged [304]; but it is clear that important considerationsmust be ac-
knowledged before moving ahead with such approaches in order to
avoid untoward side-effects to both the immune system and the brain.
6. Conclusion
It is almost 60 years since the ﬁrst cytokinewas described [305,306].
Since that time, more than 300 cytokines, chemokines, and growth fac-
tors have been described, with varying functions on not just the im-
mune system but on every organ system in the body. However in
spite of this we are still largely in our infancy in understanding how
these factors, alone and in concert with other factors, inﬂuence homeo-
static and inﬂammatory events. Continued research is therefore clearly
essential in order to better understand the complexity of these path-
ways and the pleiotropic interactions that characterise cytokine signal-
ling. Through so doing hopefully wewill eventually be able to eliminate
inﬂammatory disease processes without compromising the individual
or exposing them to other deleterious outcomes.
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